Lowest Price Guaranteed
Pages
320
Last Updated
July 2026
View Count
15546
1 PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2 EXECUTIVE SUMMARY
3 INTRODUCTION
3.1. Chapter Overview
3.2. Stem Cell Therapies
3.2.1. Classification of Stem Cells
3.2.1.1. Based on Stem Cell Potency
3.2.1.2. Based on Stem Cell Origin
3.2.1.3. Based on Stem Cell Source
3.2.2. Application of Stem Cell Therapies
3.2.3. Administration of Stem Cells Therapies
3.2.4. Commercialized Stem Cell Therapies
3.3. Stem Cell Therapy Supply Chain
3.3.1. Donor Eligibility and Selection
3.3.2. Sample Collection
3.3.3. Manufacturing
3.3.4. Logistics
3.3.5. Patient Verification and Treatment
3.4. Stem Cell Therapy Manufacturing
3.4.1. Type of Manufacturing Models
3.4.1.1. Centralized Manufacturing Model
3.4.1.2. Decentralized Manufacturing Model
3.4.2. Scalability of Manufacturing Process
3.4.2.1. Scale-Up
3.4.2.2. Scale-Out
3.4.3. Important Factors for Stem Cell Therapy Manufacturing
3.4.3.1. Characterization
3.4.3.2. Cost of Goods
3.4.4. Automation of Stem Cell Therapy Manufacturing
3.4.5. Stem Cell Therapy Contract Manufacturing
3.4.5.1. Need for Outsourcing
3.4.5.2. Advantages of Outsourcing Manufacturing Services
3.4.5.3. Basic Guidelines for Selecting a CMO Partner
3.4.6. Key Challenges and Drivers of the Stem Cell Contract Manufacturing Market
4 MARKET OVERVIEW
4.1. Chapter Overview
4.2. Stem Cell Therapy CMOs: List of Industry Players
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Location of Manufacturing Facilities
4.2.5. Analysis by Types of Services Offered
4.2.6. Analysis by Scale of Operation
4.2.7. Analysis by Type and Source of Stem Cells
4.3. Stem Cell Therapy CMOs: List of Non-Industry Players
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Location of Headquarters
4.3.3. Analysis by Location of Manufacturing Facilities
4.3.4. Analysis by Types of Services Offered
4.3.5. Analysis by Scale of Operation
4.3.6. Analysis by Types and Source of Stem Cells
4.4. Stem Cell Therapies: In-House Manufacturers
5 REGULATORY LANDSCAPE
5.1. Chapter Overview
5.2. Current Scenario
5.2.1. Regulatory System in North America
5.2.2. Regulatory System in Europe
5.2.3. Regulatory System in Japan
5.2.4. Conditional Approvals
5.3. Accreditations for Cell Therapy Manufacturing
5.3.1. Information on Facility Approvals Granted by Various Regulatory Authorities
5.4. Guidelines for Manufacturing Cell-based Therapies
5.5. Existing Challenges
5.5.1. Variability in Regulatory Guidelines across Different Geographies
6 STEM CELL THERAPY CONTRACT MANUFACTURERS IN NORTH AMERICA
6.1. Chapter Overview
6.2. FUJIFILM Cellular Dynamics
6.2.1. Company Overview
6.2.2. Financial Performance
6.2.3. Manufacturing Capabilities and Facilities
6.2.4. Recent Developments and Future outlook
6.3. GenCure
6.3.1. Company Overview
6.3.2. Manufacturing Capabilities and Facilities
6.3.3. Recent Developments and Future outlook
6.4. Progenitor Cell Therapy (PCT)
6.4.1. Company Overview
6.4.2. Financial Performance
6.4.3. Manufacturing Capabilities and Facilities
6.4.4. Recent Developments and Future outlook
6.5. Waisman Biomanufacturing
6.5.1. Company Overview
6.5.2. Manufacturing Capabilities and Facilities
6.5.3. Recent Developments and Future outlook
6.6. WuXi Advanced Therapies
6.6.1. Company Overview
6.6.2. Financial Performance
6.6.3. Manufacturing Capabilities and Facilities
6.6.4. Recent Developments and Future Outlook
7 STEM CELL THERAPY CONTRACT MANUFACTURERS IN EUROPE AND ASIA-PACIFIC
7.1. Chapter Overview
7.2. Key Player in Europe
7.2.1. BioNTech Innovative Manufacturing Services
7.2.1.1. Company Overview
7.2.1.2. Manufacturing Capabilities and Facilities
7.2.1.3. Recent Developments and Future Outlook
7.2.2. Cell and Gene Therapy Catapult
7.2.2.1. Company Overview
7.2.2.2. Manufacturing Capabilities and Facilities
7.2.2.3. Recent Developments and Future Outlook
7.2.3. Lonza
7.2.3.1. Company Overview
7.2.3.2. Financial Information
7.2.3.3. Manufacturing Capabilities and Facilities
7.2.3.4. Recent Developments and Future Outlook
7.2.4. Roslin Cells
7.2.4.1. Company Overview
7.2.4.2. Manufacturing Capabilities and Facilities
7.2.4.3. Recent Developments and Future Outlook
7.3. Key Player in Asia Pacific
7.3.1. MEDINET
7.3.1.1. Company Overview
7.3.1.2. Manufacturing Capabilities and Facilities
7.3.1.3. Recent Developments and Future Outlook
7.3.2. Nikon CeLL innovation
7.3.2.1. Company Overview
7.3.2.2. Financial Performance
7.3.2.3. Manufacturing Capabilities and Facilities
7.3.2.4. Recent Developments and Future Outlook
8 PARTNERSHIPS AND COLLABORATION
8.1. Chapter Overview
8.2. Partnership Models
8.3. Stem Cell Therapy Contract Manufacturing: List of Partnerships and Collaborations
8.3.1. Analysis by Year of Partnership
8.3.2. Analysis by Type of Partnership
8.3.3. Analysis by Type of Stem Cells
8.3.4. Analysis by Source of Stem Cells
8.3.5. Analysis by Scale of Operation
8.3.6. Most Active Players: Analysis by Number of Partnerships
8.3.7. Regional Analysis
8.3.7.1. Intercontinental and Intracontinental Agreements
9 THERAPY DEVELOPERS AND CMOs: REGIONAL ANALYSIS
9.1. Chapter Overview
9.2. Stem Cell Therapies and Developers
9.3. Therapy Developers and CMOs in North America
9.3.1. CMOs Offering Services for Preclinical Stage Molecules: North America
9.3.2. CMOs Offering Services for Clinical Stage Molecules: North America
9.3.3. CMOs Offering Services for Commercialized Molecules: North America
9.4. Therapy Developers and CMOs in Europe
9.4.1. CMOs Offering Services for Preclinical Molecules: Europe
9.4.2. CMOs Offering Services for Clinical Molecules: Europe
9.4.3. CMOs Offering Services for Commercialized Molecules: Europe
9.5. Therapy Developers and CMOs in Asia Pacific / RoW
9.5.1. CMOs Offering Services for Preclinical Molecules: Asia Pacific / RoW
9.5.2. CMOs Offering Services for Clinical Stage Molecules: Asia Pacific / RoW
9.5.3. CMOs Offering Services for Commercialized Molecules: Asia Pacific / RoW
10 CAPACITY ANALYSIS
10.1. Chapter Overview
10.2. Assumptions and Methodology
10.3. Stem Cell Contract Manufacturing Market (Industry Players): Global Production Capacity in Terms of Number of Cleanrooms
10.3.1. Analysis by Size of the CMO
10.3.2. Analysis by Scale of Operation
10.3.3. Analysis by Region
10.4. Stem Cell Contract Manufacturing Market (Industry Players): Global Production Capacity in Terms of Area of Cleanrooms
10.4.1. Analysis by Size of the CMO
10.4.2. Analysis by Scale of Operation
10.4.3. Analysis by Region
10.5. Stem Cell Therapy Contract Manufacturing (Non-Industry Players): Global Production Capacity in Terms of Number of Cleanrooms
10.5.1. Analysis by Scale of Operation
10.5.2. Analysis by Region
10.6. Stem Cell Therapy Contract Manufacturing (Non-Industry Players): Global Production Capacity in Terms of Area of Cleanrooms
10.6.1. Analysis by Scale of Operation
10.6.2. Analysis by Region
10.7. Conclusion
11 DEMAND ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Global Clinical Demand for Stem Cell Therapy Manufacturing
11.3.1. Analysis by Types of Stem Cells
11.3.2. Analysis by Source of Stem Cells
11.3.3. Analysis by Geographical Location
11.4. Global Commercial Demand for Stem Cell Therapy Manufacturing
11.4.1. Analysis by Types of Stem Cells
11.4.2. Analysis by Source of Stem Cells
11.4.3. Analysis by Geographical Location
12 MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030
12.4. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells
12.5. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells
12.6. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation
12.7. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Company Size
12.8. Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Geography
12.8.1. Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030
12.8.1.1. Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030
12.8.1.2. Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030
12.8.1.3. Stem Cell Therapy Contract Manufacturing Market in North America For Induced Pluripotent Stem Cell-based Therapies, 2019-2030
12.8.1.4. Stem Cell Therapy Contract Manufacturing Market in North America For Allogeneic Stem Cell Therapies, 2019-2030
12.8.1.5. Stem Cell Therapy Contract Manufacturing Market in North America For Autologous Stem Cell Therapies, 2019-2030
12.8.1.6. Stem Cell Therapy Contract Manufacturing Market in North America, for Preclinical / Clinical Scale Operations, 2019-2030
12.8.1.7. Stem Cell Therapy Contract Manufacturing Market in North America, for Commercial Scale Operations, 2019-2030
12.8.1.8. Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030
12.8.1.9. Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030
12.8.1.10. Stem Cell Therapy Contract Manufacturing Market in North America for Large Companies, 2019-2030
12.8.2. Stem Cell Therapy Contract Manufacturing in Europe, 2019-2030
12.8.2.1. Stem Cell Therapy Contract Manufacturing in Europe for Adult Stem Cell-based Therapies, 2019-2030
12.8.2.2. Stem Cell Therapy Contract Manufacturing in Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030
12.8.2.3. Stem Cell Therapy Contract Manufacturing Market in Europe For Induced Pluripotent Stem Cell-based Therapies, 2019-2030
12.8.2.4. Stem Cell Therapy Contract Manufacturing Market in Europe For Allogeneic Stem Cell Therapies, 2019-2030
12.8.2.5. Stem Cell Therapy Contract Manufacturing Market in Europe For Autologous Stem Cell Therapies, 2019-2030
12.8.2.6. Stem Cell Therapy Contract Manufacturing Market in Europe, for Preclinical / Clinical Scale Operations, 2019-2030
12.8.2.7. Stem Cell Therapy Contract Manufacturing Market in Europe, for Commercial Scale Operations, 2019-2030
12.8.2.8. Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030
12.8.2.9. Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030
12.8.2.10. Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030
12.8.3. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, 2019-2030
12.8.3.1. Stem Cell Therapy Contract Manufacturing in Asia and Rest of the World for Adult Stem Cell-based Therapies, 2019-2030
12.8.3.2. Stem Cell Therapy Contract Manufacturing in Market in Asia and Rest of the World for Embryonic Stem Cell-based Therapies, 2019-2030
12.8.3.3. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030
12.8.3.4. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Allogeneic Stem Cell Therapies, 2019-2030
12.8.3.5. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Autologous Stem Cell Therapies, 2019-2030
12.8.3.6. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, for Preclinical / Clinical Scale Operations, 2019-2030
12.8.3.7. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, for Commercial Scale Operations, 2019-2030
12.8.3.8. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030
12.8.3.9. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030
12.8.3.10. Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Large Companies, 2019-2030
13 KEY PERFORMANCE INDICATORS
13.1. Chapter Overview
13.2. Stem Cell Therapy Contract Manufacturers: Key Performance Indicators
13.2.1. Financial Indicators
13.2.1.1. Big Pharma Perspective
13.2.1.2. Contract Manufacturers’ Perspective
13.2.2. Process and Capability Indicators
13.2.2.1. Big Pharma Perspective
13.2.2.2. Contract Manufacturers’ Perspective
13.2.3. Market Reputation Indicators
13.2.3.1. Big Pharma Perspective
13.2.3.2. Contract Manufacturers’ Perspective
13.3. Conclusion
14 CONCLUDING REMARKS
14.1. Chapter Overview
14.2. Key Takeaways
15 EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Bio Elpida
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Gilles Devillers, General Manager
15.3. Kadimastem
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Arik Hasson, Executive VP Research and Development
15.4. RoslinCT
15.4.1. Company Snapshot
15.4.2. Interview Transcript: Fiona Bellot, Business Development Manager
15.5. University of Minnesota
15.5.1. Company Snapshot
15.5.2. Interview Transcript: David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine
15.6. Waisman Biomanufacturing
15.6.1. Company Snapshot
15.6.2. Interview Transcript: Brian Dattilo, Manager of Business Development
15.7. Yposkesi
15.7.1. Company Snapshot
15.7.2. Interview Transcript: Mathilde Girard, Department Leader, Cell Therapy Innovation and Development
16. APPENDIX 1: TABULATED DATA
17. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Evolution of Stem Cell Research
Figure 3.2 Classification of Stem Cells
Figure 3.3 Potential Application Areas for Stem Cell Therapies
Figure 3.4 Key Processes in the Stem Cell Therapies Supply Chain
Figure 3.5 Key Steps Involved in the Manufacturing of Stem Cell Therapies
Figure 3.6 Keys Steps Involved in the Logistic Operations of Autologous Therapies
Figure 3.7 Centralized Manufacturing: Process Model
Figure 3.8 Decentralized Manufacturing: Process Model
Figure 3.9 Types of Contract Manufacturers
Figure 3.10 Key Factors to Consider while Selecting a CMO Partner
Figure 3.11 Stem Cell Therapy: Challenges and Drivers
Figure 4.1 Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
Figure 4.2 Stem Cell Therapy CMOs (Industry): Distribution by Company Size
Figure 4.3 Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
Figure 4.4 Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facility
Figure 4.5 Stem Cell Therapy CMOs (Industry): Distribution by Types of Services Offered
Figure 4.6 Stem Cell Therapy CMOs (Industry): Distribution by Scale of Operation
Figure 4.7 Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cells Used
Figure 4.8 Stem Cell Therapy CMOs (Industry): Distribution by Type of Stem Cells Used
Figure 4.9 Stem Cell Therapy CMOs (Non-Industry): Distribution by Year of Establishment
Figure 4.10 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Headquarters
Figure 4.11 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Manufacturing Facility
Figure 4.12 Stem Cell Therapy CMOs (Non-Industry): Distribution by Types of Services Offered
Figure 4.13 Stem Cell Therapy CMOs (Non-Industry): Distribution by Scale of Operation
Figure 4.14 Stem Cell Therapy CMOs (Non-Industry): Distribution by Source of Stem Cells
Figure 4.15 Stem Cell Therapy CMOs (Non-Industry): Distribution by Type of Stem Cells Used
Figure 5.1 Stem Cell Therapy Contract Manufacturing: Distribution of Manufacturing Facilities by Regulatory Authorities
Figure 6.1 FUJIFILM Cellular Dynamics: Annual Revenues, 2014- Q1 2019 (JPY Billion)
Figure 6.2 Hitachi Chemical (Progenitor Cell Therapy): Annual Revenues, 2015- Q1 2019 (YEN Billion)
Figure 6.3 WuXi AppTec: Annual Revenues, 2015- 2018 (RMB Million)
Figure 7.1 Lonza: Annual Revenues, 2012- 2018 (CHF Million)
Figure 7.2 Nikon CeLL innovation: Annual Revenues, 2015- 2018 (YEN Million)
Figure 8.1 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2019
Figure 8.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 8.3 Partnerships and Collaborations: Type of Partnership and Year (2015-2019)
Figure 8.4 Partnerships and Collaborations: Distribution by Type of Stem Cells
Figure 8.5 Partnerships and Collaborations: Distribution by Source of Stem Cells and Type of Partnership
Figure 8.6 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Figure 8.7 Partnerships and Collaborations: Most Active Players
Figure 8.8 Partnerships and Collaborations: Regional Distribution
Figure 8.9 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 9.1 Therapy Developers and CMOs in North America
Figure 9.2 Therapy Developers and CMOs in Europe
Figure 9.3 Therapy Developers and CMOs in Asia Pacific / RoW
Figure 10.1 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
Figure 10.2 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
Figure 10.3 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms: Distribution by Company Size (Sample Data Set for Industry Players)
Figure 10.4 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
Figure 10.5 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
Figure 10.6 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facilities
Figure 10.7 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
Figure 10.8 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Figure 10.9 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Location of Manufacturing Facilities
Figure 10.10 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
Figure 10.11 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
Figure 10.12 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facilities
Figure 10.13 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
Figure 10.14 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
Figure 10.15 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facilities
Figure 11.1 Global Clinical Demand for Stem Cell Therapies, 2019-2030 (Billion Cells)
Figure 11.2 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Type of Stem Cells (Billion Cells)
Figure 11.3 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Source of Stem Cells (Billion Cells)
Figure 11.4 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Geographical Location (Billion Cells)
Figure 11.5 Global Commercial Demand for Stem Cell Therapies, 2019-2030 (Billion Cells)
Figure 11.6 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Type of Stem Cells (Billion Cells)
Figure 11.7 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Source of Stem Cells (Billion Cells)
Figure 11.8 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Geographical Location (Billion Cells)
Figure 12.1 Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030 (USD Million)
Figure 12.2 Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells (USD Million)
Figure 12.3 Global Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells (USD Million)
Figure 12.4 Global Stem Cell Therapy Contract Manufacturing Market: Distribution by Scale of Operation, 2019-2030 (USD Million)
Figure 12.5 Global Stem Cell Therapy Contract Manufacturing Market: Distribution by Company Size, 2019-2030 (USD Million)
Figure 12.6 Global Stem Cell Therapy Contract Manufacturing Market: Distribution by Geography, 2019-2030 (USD Million)
Figure 12.7 Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030 (USD Million)
Figure 12.8 Stem Cell Therapy Contract Manufacturing Market in the US, 2019-2030 (USD Million)
Figure 12.9 Stem Cell Therapy Contract Manufacturing Market in the Canada, 2019-2030 (USD Million)
Figure 12.10 Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.11 Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.12 Stem Cell Therapy Contract Manufacturing Market in North America for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.13 Stem Cell Therapy Contract Manufacturing Market in North America for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.14 Stem Cell Therapy Contract Manufacturing Market in North America for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.15 Stem Cell Therapy Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Figure 12.16 Stem Cell Therapy Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
Figure 12.17 Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
Figure 12.18 Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
Figure 12.19 Stem Cell Therapy Contract Manufacturing Market in North America for Large Companies, 2019-2030 (USD Million)
Figure 12.20 Stem Cell Therapy Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
Figure 12.21 Stem Cell Therapy Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
Figure 12.22 Stem Cell Therapy Contract Manufacturing Market in France, 2019-2030 (USD Million)
Figure 12.23 Stem Cell Therapy Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
Figure 12.24 Stem Cell Therapy Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
Figure 12.25 Stem Cell Therapy Contract Manufacturing Market Rest of Europe, 2019-2030 (USD Million)
Figure 12.26 Stem Cell Therapy Contract Manufacturing Market in Europe for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.27 Stem Cell Therapy Contract Manufacturing Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.28 Stem Cell Therapy Contract Manufacturing Market in Europe for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.29 Stem Cell Therapy Contract Manufacturing Market in Europe for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.30 Stem Cell Therapy Contract Manufacturing Market in Europe for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.31 Stem Cell Therapy Contract Manufacturing Market in Europe for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Figure 12.32 Stem Cell Therapy Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
Figure 12.33 Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
Figure 12.34 Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
Figure 12.35 Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030 (USD Million)
Figure 12.36 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World, 2019-2030 (USD Million)
Figure 12.37 Stem Cell Therapy Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
Figure 12.38 Stem Cell Therapy Contract Manufacturing Market in Rest of Asia-Pacific, 2019-2030 (USD Million)
Figure 12.39 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.40 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.41 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Figure 12.42 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.43 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Figure 12.44 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Figure 12.45 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Commercial Scale Operations, 2019-2030 (USD Million)
Figure 12.46 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030 (USD Million)
Figure 12.47 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030 (USD Million)
Figure 12.48 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Large Companies, 2019-2030 (USD Million)
Figure 13.1 Stem Cell Therapy Contract Manufacturers: Key Performance Indicators (KPIs)
Figure 13.2 Financial Indicators: Comparative Analysis of KPIs Considered by Big Pharma Companies
Figure 13.3 Financial Indicators: Big Pharma Perspective
Figure 13.4 Financial Indicators: Contract Manufacturers’ Perspective
Figure 13.5 Process / Capability Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.6 Process / Capability Indicators: Big Pharma Perspective
Figure 13.7 Process / Capability Indicators: Contract Manufacturers’ Perspective
Figure 13.8 Market Reputation Indicators: Comparative Analysis of KPIs of Big Pharma Companies
Figure 13.9 Market Reputation Indicators: Big Pharma Perspective
Figure 13.10 Market Reputation Indicators: Contract Manufacturers’ Perspective
Table 3.1 Differences between Stem Cell Therapies and Biotechnology Products
Table 3.2 Stem Cell Therapies: Approved Products,
Table 3.3 Assessment Strategies for Different Manufacturing Processes
Table 3.4 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 4.1 Stem Cell Therapy Contract Manufacturers: List of Industry Players
Table 4.2 Stem Cell Therapy Contract Manufacturers: List of Industry Players
Table 4.3 Stem Cell Therapy CMOs: Information on Type of Services Offered (Industry Players)
Table 4.4 Stem Cell Therapy CMOs: Information on Scale of Operation (Industry Players)
Table 4.5 Stem Cell Therapy CMOs: Information on Type and Source of Stem Cells Used (Industry Players)
Table 4.6 Stem Cell Therapy Contract Manufacturers: List of Non-Industry Players
Table 4.7 Stem Cell Therapy CMOs: Information on Type of Services Offered (Non-Industry Players)
Table 4.8 Stem Cell Therapy CMOs: Information on Scale of Operation (Non-Industry Players)
Table 4.9 Stem Cell Therapy CMOs: Information on Type and Source of Stem Cells Used (Non-Industry Players)
Table 4.10 Stem Cell Therapies: List of In-House Manufacturers
Table 5.1 Stem Cell Therapy Manufacturing: Regulatory Authorities
Table 5.2 Cell Therapy: Regulatory Considerations
Table 6.1 Stem Cell CMOs: List of Profiled Companies in North America
Table 6.2 FUJIFILM Cellular Dynamics: Company Overview
Table 6.3 FUJIFILM Cellular Dynamics: Overview of Manufacturing Capabilities
Table 6.4 FUJIFILM Cellular Dynamics: Recent Development and Future Outlook
Table 6.5 GenCure: Company Overview
Table 6.6 GenCure: Overview of Manufacturing Capabilities
Table 6.7 GenCure: Recent Development and Future Outlook
Table 6.8 Progenitor Cell Therapy: Company Overview
Table 6.9 Progenitor Cell Therapy: Overview of Manufacturing Capabilities
Table 6.10 Progenitor Cell Therapy: Recent Development and Future Outlook
Table 6.11 Waisman Biomanufacturing: Company Overview
Table 6.12 Waisman Biomanufacturing: Overview of Manufacturing Capabilities
Table 6.13 Waisman Biomanufacturing: Recent Development and Future Outlook
Table 6.14 WuXi Advanced Therapies: Company Overview
Table 6.15 WuXi Advanced Therapies: Overview of Manufacturing Capabilities
Table 6.16 WuXi Advanced Therapies: Recent Development and Future Outlook
Table 7.1 Stem Cell CMOs: List of Profiled Companies in Europe and Asia
Table 7.2 BioNTech Innovative Manufacturing Services: Company Overview
Table 7.3 BioNTech Innovative Manufacturing Services: Overview of Manufacturing Capabilities
Table 7.4 BioNTech Innovative Manufacturing Services: Recent Development and Future Outlook
Table 7.5 Cell and Gene Therapy Catapult: Company Overview
Table 7.6 Cell and Gene Therapy Catapult: Overview of Manufacturing Capabilities
Table 7.7 Company Cell and Gene Therapy Catapult: Recent Development and Future Outlook
Table 7.8 Lonza: Company Overview
Table 7.9 Lonza: Overview of Manufacturing Capabilities
Table 7.10 Lonza: Recent Development and Future Outlook
Table 7.11 RoslinCT: Company Overview
Table 7.12 RoslinCT: Overview of Manufacturing Capabilities
Table 7.13 RoslinCT: Recent Development and Future Outlook
Table 7.14 MEDINET: Company Overview
Table 7.15 MEDINET: Overview of Manufacturing Capabilities
Table 7.16 MEDINET: Recent Development and Future Outlook
Table 7.17 Nikon CeLL innovation: Company Overview
Table 7.18 Nikon CeLL innovation: Overview of Manufacturing Capabilities
Table 7.19 Nikon CeLL innovation: Recent Development and Future Outlook
Table 8.1 Stem Cell Therapy Contract Manufacturing: Partnerships and Collaborations, 2015-2019
Table 9.1 List of Stem Cell Therapies and their Developers
Table 9.2 CMOs Offering Services for Preclinical Stage Molecules: North America
Table 9.3 CMOs Offering Services for Clinical Stage Molecules: North America
Table 9.4 CMOs Offering Services for Preclinical Molecules: Europe
Table 9.5 CMOs Offering Services for Clinical Molecules: Europe
Table 9.6 CMOs Offering Services for Preclinical Molecules: Asia Pacific / RoW
Table 9.7 CMOs Offering Services for Clinical Stage Molecules: Asia Pacific / RoW
Table 10.1 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Size of Manufacturers (Sample Data Set for Industry Players)
Table 10.2 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms: Average Capacity by Size of Manufacturers (Sample Data Set for Industry Players)
Table 10.3 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry): Distribution by Size of Manufacturers
Table 10.4 Stem Cell Therapy Installed Manufacturing Capacity in Terms of Area of Cleanrooms (Industry): Distribution by Size of Manufacturers
Table 10.5 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry): Average Capacity
Table 10.6 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms (Non-Industry): Average Capacity
Table 15.1 Bio Elpida: Key Highlights
Table 15.2 Kadimastem: Key Highlights
Table 15.3 RoslinCT: Key Highlights
Table 15.4 University of Minnesota: Key Highlights
Table 15.5 Waisman Biomanufacturing: Key Highlights
Table 15.6 Yposkesi: Company Snapshot
Table 16.1 Stem Cell Therapy CMOs (Industry): Distribution by Year of Establishment
Table 16.2 Stem Cell Therapy CMOs (Industry): Distribution by Size of Employee Base
Table 16.3 Stem Cell Therapy CMOs (Industry): Distribution by Location of Headquarters
Table 16.4 Stem Cell Therapy CMOs (Industry): Distribution by Location of Manufacturing Facility
Table 16.5 Stem Cell Therapy CMOs (Industry): Distribution by Type of Services Offered
Table 16.6 Stem Cell Therapy CMOs (Industry): Distribution by Scale of Operation
Table 16.7 Stem Cell Therapy CMOs (Industry): Distribution by Source of Stem Cells Used
Table 16.8 Stem Cell Therapy CMOs (Industry): Distribution by Type of Stem Cells Used
Table 16.9 Stem Cell Therapy CMOs (Non-Industry): Distribution by Year of Establishment
Table 16.10 Stem Cell Therapy CMOs (Non-Industry): Distribution by Location of Headquarters (Region-wise)
Table 16.11 Stem Cell Therapy CMOs: Distribution by Location of Manufacturing Facility (Region-wise)
Table 16.12 Stem Cell Therapy CMOs: Distribution by Type of Services Offered
Table 16.13 Stem Cell Therapy CMOs (Non-Industry): Distribution by Scale of Operation
Table 16.14 Stem Cell Therapy CMOs (Non-Industry): Distribution by Source of Stem Cells Used
Table 16.15 Stem Cell Therapy CMOs (Non-Industry): Distribution by Type of Stem Cells Used
Table 16.16 Stem Cell Therapy Contract Manufacturing: Distribution of Manufacturing Facilities by Regulatory Authorities
Table 16.17 FUJIFILM Cellular Dynamics: Annual Revenues, 2012-Q1 2019 (JPY Billion)
Table 16.18 Hitachi Chemical (Progenitor Cell Therapy): Annual Revenues, 2015- Q1 2019 (YEN Billion)
Table 16.19 WuXi AppTec: Annual Revenues, 2015- 2018 (RMB Million)
Table 16.20 Lonza: Annual Revenues, 2012- 2018 (CHF Million)
Table 16.21 Nikon CeLL innovation: Annual Revenues, 2015- 2018 (YEN Million)
Table 16.22 Partnerships and Collaborations: Cumulative Trend by Year, 2013-2019
Table 16.23 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.24 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2019)
Table 16.25 Partnerships and Collaborations: Distribution by Type of Stem Cells
Table 16.26 Partnerships and Collaborations: Distribution by Source of Stem Cells and Type of Partnership
Table 16.27 Partnerships and Collaborations: Distribution by Scale of Operation and Type of Partnership
Table 16.28 Partnerships and Collaborations: Most Active Players
Table 16.29 Partnership and Collaborations: Regional Distribution
Table 16.30 Contract Manufacturing Opportunity Assessment in North America
Table 16.31 Contract Manufacturing Opportunity Assessment in Europe
Table 16.32 Contract Manufacturing Opportunity Assessment in Asia Pacific / RoW
Table 16.33 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
Table 16.34 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Industry Players)
Table 16.35 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Area of Cleanrooms: Distribution by Company Size (Sample Data Set for Industry Players)
Table 16.36 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Company Size
Table 16.37 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Scale of Operation
Table 16.38 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Industry Players): Distribution by Location of Manufacturing Facilities
Table 16.39 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Company Size
Table 16.40 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Table 16.41 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Industry Players): Distribution by Scale of Operation
Table 16.42 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
Table 16.43 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Scale of Operation
Table 16.44 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Number of Cleanrooms (Non-Industry Players): Distribution by Location of Manufacturing Facilities
Table 16.45 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area: Distribution by Range of Installed Capacity (Sample Data Set for Non-Industry Players)
Table 16.46 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Scale of Operation
Table 16.47 Stem Cell Therapy CMOs Installed Global Capacity in Terms of Cleanroom Area (Non-Industry Players): Distribution by Location of Manufacturing Facilities
Table 16.48 Global Clinical Demand for Stem Cell Therapies, 2019-2030 (Billion Cells)
Table 16.49 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Type of Stem Cells (Billion Cells)
Table 16.50 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Source of Stem Cells (Billion Cells)
Table 16.51 Global Clinical Demand for Stem Cell Therapies, 2019-2030: Distribution by Geographical Location (Billion Cells)
Table 16.52 Global Commercial Demand for Stem Cell Therapies, 2019-2030 (Billion Cells)
Table 16.53 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Type of Stem Cells (Billion Cells)
Table 16.54 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Source of Stem Cells (Billion Cells)
Table 16.55 Global Commercial Demand for Stem Cell Therapies, 2019-2030: Distribution by Geographical Location (Billion Cells)
Table 16.56 Overall Stem Cell Therapy Contract Manufacturing Market, 2019-2030 (USD Million)
Table 16.57 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Types of Stem Cells (USD Million)
Table 16.58 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Source of Stem Cells (USD Million)
Table 16.59 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Scale of Operation (USD Million)
Table 16.60 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Company Size (USD Million)
Table 16.61 Stem Cell Therapy Contract Manufacturing Market, 2019-2030: Distribution by Geography (USD Million)
Table 16.62 Stem Cell Therapy Contract Manufacturing Market in North America, 2019-2030 (USD Million)
Table 16.63 Stem Cell Therapy Contract Manufacturing Market in US, 2019-2030 (USD Million)
Table 16.64 Stem Cell Therapy Contract Manufacturing Market in Canada, 2019-2030 (USD Million)
Table 16.65 Stem Cell Therapy Contract Manufacturing Market in North America for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.66 Stem Cell Therapy Contract Manufacturing Market in North America for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.67 Stem Cell Therapy Contract Manufacturing Market in North America for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.68 Stem Cell Therapy Contract Manufacturing Market in North America for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.69 Stem Cell Therapy Contract Manufacturing Market in North America for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.70 Stem Cell Therapy Contract Manufacturing Market in North America for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Table 16.71 Stem Cell Therapy Contract Manufacturing Market in North America for Commercial Operations, 2019-2030 (USD Million)
Table 16.72 Stem Cell Therapy Contract Manufacturing Market in North America for Small-sized Companies, 2019-2030 (USD Million)
Table 16.73 Stem Cell Therapy Contract Manufacturing Market in North America for Mid-sized Companies, 2019-2030 (USD Million)
Table 16.74 Stem Cell Therapy Contract Manufacturing Market in North America For Large Companies, 2019-2030 (USD Million)
Table 16.75 Stem Cell Therapy Contract Manufacturing Market in Europe, 2019-2030 (USD Million)
Table 16.76 Stem Cell Therapy Contract Manufacturing Market in Germany, 2019-2030 (USD Million)
Table 16.77 Stem Cell Therapy Contract Manufacturing Market in France, 2019-2030 (USD Million)
Table 16.78 Stem Cell Therapy Contract Manufacturing Market in Spain, 2019-2030 (USD Million)
Table 16.79 Stem Cell Therapy Contract Manufacturing Market in the UK, 2019-2030 (USD Million)
Table 16.80 Stem Cell Therapy Contract Manufacturing Market in Rest of the Europe, 2019-2030 (USD Million)
Table 16.81 Stem Cell Therapy Contract Manufacturing Market in Europe for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.82 Stem Cell Therapy Contract Manufacturing Market in Europe for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.83 Stem Cell Therapy Contract Manufacturing Market in Europe for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.84 Stem Cell Therapy Contract Manufacturing Market in Europe for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.85 Stem Cell Therapy Contract Manufacturing Market in Europe for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.86 Stem Cell Therapy Contract Manufacturing Market in Europe for Preclinical / Clinical Operations, 2019-2030 (USD Million)
Table 16.87 Stem Cell Therapy Contract Manufacturing Market in Europe for Commercial Operations, 2019-2030 (USD Million)
Table 16.88 Stem Cell Therapy Contract Manufacturing Market in Europe for Small-sized Companies, 2019-2030 (USD Million)
Table 16.89 Stem Cell Therapy Contract Manufacturing Market in Europe for Mid-sized Companies, 2019-2030 (USD Million)
Table 16.90 Stem Cell Therapy Contract Manufacturing Market in Europe for Large Companies, 2019-2030 (USD Million)
Table 16.91 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The Europe, 2019-2030 (USD Million)
Table 16.92 Stem Cell Therapy Contract Manufacturing Market in Japan, 2019-2030 (USD Million)
Table 16.93 Stem Cell Therapy Contract Manufacturing Market in Rest of The World, 2019-2030 (USD Million)
Table 16.94 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Adult Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.95 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Embryonic Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.96 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Induced Pluripotent Stem Cell-based Therapies, 2019-2030 (USD Million)
Table 16.97 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Allogenic Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.98 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of The World for Autologous Stem Cell Therapies, 2019-2030 (USD Million)
Table 16.99 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Preclinical / Clinical Scale Operations, 2019-2030 (USD Million)
Table 16.100 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Commercial Scale Operations, 2019-2030 (USD Million)
Table 16.101 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Small-sized Companies, 2019-2030 (USD Million)
Table 16.102 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Mid-sized Companies, 2019-2030 (USD Million)
Table 16.103 Stem Cell Therapy Contract Manufacturing Market in Asia and Rest of the World for Large Companies, 2019-2030 (USD Million)
Please reach out to our team for the details